- Home
- STTK vs CIIT Comparison
STTK vs CIIT Comparison
Compare STTK & CIIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- CIIT
- Stock Information
- Founded
- STTK 2016
- CIIT N/A
- Country
- STTK United States
- CIIT Hong Kong
- Employees
- STTK N/A
- CIIT N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- CIIT
- Sector
- STTK Health Care
- CIIT
- Exchange
- STTK Nasdaq
- CIIT NYSE
- Market Cap
- STTK 37.6M
- CIIT 34.6M
- IPO Year
- STTK 2020
- CIIT N/A
- Fundamental
- Price
- STTK $1.00
- CIIT $2.01
- Analyst Decision
- STTK Hold
- CIIT
- Analyst Count
- STTK 4
- CIIT 0
- Target Price
- STTK $3.00
- CIIT N/A
- AVG Volume (30 Days)
- STTK 112.0K
- CIIT 170.3K
- Earning Date
- STTK 07-31-2025
- CIIT 06-09-2025
- Dividend Yield
- STTK N/A
- CIIT N/A
- EPS Growth
- STTK N/A
- CIIT N/A
- EPS
- STTK N/A
- CIIT N/A
- Revenue
- STTK $4,606,000.00
- CIIT $9,464,501.00
- Revenue This Year
- STTK N/A
- CIIT N/A
- Revenue Next Year
- STTK N/A
- CIIT N/A
- P/E Ratio
- STTK N/A
- CIIT N/A
- Revenue Growth
- STTK 69.65
- CIIT 51.52
- 52 Week Low
- STTK $0.69
- CIIT $1.60
- 52 Week High
- STTK $4.99
- CIIT $5.38
- Technical
- Relative Strength Index (RSI)
- STTK 47.54
- CIIT N/A
- Support Level
- STTK $0.91
- CIIT N/A
- Resistance Level
- STTK $1.14
- CIIT N/A
- Average True Range (ATR)
- STTK 0.08
- CIIT 0.00
- MACD
- STTK -0.01
- CIIT 0.00
- Stochastic Oscillator
- STTK 28.35
- CIIT 0.00
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About CIIT TIANCI INTERNATIONAL INC
Tianci International Inc along with its subsidiaries is engaged in sale of components of electronic devices, development of software and websites, technical consulting, and providing maintenance support on customized software. The company's business is predominantly carried out in Hong Kong with a substantial portion of its overall revenue being generated from its Electronic Device Hardware Components Sales segment.